Page 66 - Demo

PRODUCT
ULTRABIOTIC FEMI+
BioCeuticals
Bacterial imbalances of the
vagina and urogenital tract can
affect the health of the vaginal
environment, and are often
the cause of general vaginal
discomfort, with many women
experiencing imbalance at some
point in their lives. UltraBiotic
FEMI+ may help to remedy this imbalance,
and encourage the growth of good bacteria in the urogenital tract according to BioCeuticals. UltraBiotic FEMI+ contains a combination of six probiotics and Lactobacillus plantarum which, when delivered vaginally, may increase numbers of good bacteria.
BioCeuticals Education Manager Belinda Reynolds said imbalances in vaginal microflora were surprisingly common, and could be caused by fluctuations in oestrogen levels (during menopause, pregnancy and different times of the menstrual cycle), sexual activity and hygiene practices.
Probiotics can be delivered vaginally or orally, however probiotics delivered in a pessary form (a capsule inserted locally into the vagina)
may work more quickly than those taken orally as oral probiotics need to pass through the gastrointestinal tract first before reaching the urogenital tract.
LENVIMA
Eisai
Australians living with progressive, locally advanced or metastatic symptomatic radioactive iodine refractory differentiated thyroid cancer (RAI refractory DTC) now have access to Lenvima (lenvatinib). It was listed on the Pharmaceutical Benefits Scheme (PBS) from 1 December. RAI refractory DTC is a difficult to treat condition with a poor prognosis and Lenvima is a new option for patients.1 It is the first and only therapy for RAI refractory DTC to receive reimbursement from the PBS.
Lenvatinib is a multiple receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, the platelet derived growth factor (PDGF) receptor PDGFRα, KIT, and RET.2
Lenvima is registered in Australia by the Therapeutic Goods Authority (TGA) for the treatment of patients with progressive locally advanced or metastatic, differentiated thyroid cancer (DTC) refractory to radioactive iodine (RAI).2
Approximately 2,500 people in Australia are estimated to be diagnosed with thyroid cancer each year. Although thyroid cancer is rare, incidence rates have risen for both males and females over the past two decades. Females are three times more likely than males to develop thyroid cancer, making it the eighth leading cause of cancer in females in Australia.
References
1. Shah JP, et al. New and emerging therapeutic options for thyroid carcinoma. At: www.ncbi.nlm.nih.gov/ pubmed/25856096 Accessed: Dec 2016.
2. Lenvima Product Information, Mar 2016.
CORRECTION
Prezcobix
Janssen
In the December issue Prescobix was reported as being PBS listed from October 2017. This should have been October 2016.
Items in the Product news section are prepared from information provided by the companies named in each item. They are included for the information of PSA members. It is up to the individual member to use their professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses nor confirms claims made in the items. (Where provided by the company references citing evidence are included with the items.)
Advertising policy
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does not constitute an endorsement by PSA of the claims, products or services.
Australia’s highest rated pharmacy publication
Community pharmacists value and use Australian Pharmacist for six of their top seven information needs.
Most credible for patient counselling, S2 S3 medicines, professional services, clinical information, prescription medicines and CPD (education).
Pharmacy Publications & Media 2016. Competitive Advantage Research, July 2016
TO ADVERTISE CONTACT
mediakit@tremedia.com.au | Jonathon Tremain 02 9988 4689 | Amanda Bennetts 0402 055 022 | Jeff Johnston 02 9871 5520
64 Australian Pharmacist January 2017 I ©Pharmaceutical Society of Australia Ltd.
AUSTRALIAN PHARMACIST October 2016 Musculoskeletal issues The quest for new antibiotics is
AUSTRALIA’S MOST CLOSELY READ PHARMACY JOURNAL
OCTOBER 2016
V35#10
OCT 2016
Musculoskeletal
The evidence: Omega-3 and -6 fatty acids, and turmeric
Old drug new indication
The quest for new antibiotics is underway
Propanolol for forgetting the fear after trauma?
CPD:
issues